PMID: 9546009Apr 18, 1998

Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III

The American Journal of Psychiatry
Peter N van HartenR S Kahn

Abstract

The authors examined the association between three lifetime medication variables (cumulative amount of neuroleptics, number of interruptions in neuroleptic treatment, cumulative amount of anticholinergics) and the occurrence and severity of tardive dyskinesia. The study was conducted in the only psychiatric hospital of a well-defined catchment area (the Netherlands Antilles). For all patients who had a history of taking neuroleptics for at least 3 months and were currently using neuroleptics (N = 133, mean age = 51.5 years), the presence and severity of tardive dyskinesia were measured with the Abnormal Involuntary Movement Scale. Of the three lifetime medication variables, only the number of neuroleptic interruptions was significantly related to tardive dyskinesia. The risk of tardive dyskinesia was three times as great for patients with more than two neuroleptic interruptions as for patients with two or fewer interruptions. This finding supports the schizophrenia protocol of long-term neuroleptic treatment rather than targeted or intermittent neuroleptic treatment.

Citations

Mar 10, 2006·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Jack J Chen, Kelly C Lee
Jun 17, 2003·Journal of the American Medical Directors Association·Richard J Goldberg
Mar 15, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Daniel Tarsy, Ross J Baldessarini
Feb 12, 2005·Biological Psychiatry·Peter TurroneJosé N Nobrega
May 13, 2014·Asian Journal of Psychiatry·Rashmin M AchaliaOm Prakash
Feb 12, 2013·BMC Psychiatry·Robin EmsleyBrian H Harvey
May 31, 2001·Acta Psychiatrica Scandinavica·L J Bosveld-van HaandelR J van den Bosch
Jul 3, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Peter TurroneJosé N Nobrega
Nov 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Jennifer HallidayRobin McCreadie
Jul 14, 2001·The British Journal of Psychiatry. Supplement·J Cookson
Nov 25, 2003·International Journal of Urology : Official Journal of the Japanese Urological Association·Mustafa Ozgür TanIbrahim Bozkirli
Aug 23, 2018·Frontiers in Psychiatry·Anne B KoopmansPeter N van Harten
Oct 26, 2018·Drugs & Aging·Carlos Estevez-FragaJose Luis López-Sendón Moreno
May 23, 2002·Clinical Neuropharmacology·Robert L Rodnitzky
Jun 20, 2019·Current Protocols in Neuroscience·Fausto Pierdoná GuzenDayane Pessoa de Araújo
Dec 21, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Howard C MargoleseLawrence Annable

Related Concepts

Drug Administration Schedule
Dyskinesia, Medication-Induced
Schizophrenia
Severity of Illness Index
Antipsychotic Effect
Confidence Intervals
Odds Ratio
Cholinergic Antagonists

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here